bioMérieux launches leading endocrinology testing offer
dedicated to enhancing equine health
With two hormone immunoassay tests, VIDAS® Equine ACTH and VIDAS® Equine INSULIN,
bioMérieux makes laboratory standard results achievable directly at the Point of Care.

Marcy-l’Étoile, France – December 4th, 2025 – bioMérieux, a world leader in the field
of in vitro diagnostics, today announced the launch of its immunoassay
endocrinology offer for equine health, consisting of VIDAS® Equine INSULIN and
VIDAS® Equine ACTH.

By providing fast and accurate test results of insulin levels in approximately 20 minutes,
VIDAS® Equine INSULIN will help with the diagnosis and effective management of
Equine Metabolic Syndrome (EMS), commonly associated with insulin dysregulation in
horses. VIDAS® Equine ACTH provides dysregulation level testing of the
adrenocorticotropic (ACTH) hormone related to the development of Equine Cushing’s
Disease (correctly known as Pituitary Pars Intermedia Dysfunction - PPID) in just about
45 minutes. Between 18%-27%1 of horses over 15 years old show symptoms related to
Cushing’s or insulin dysregulation. Those common equine endocrine disorders can
increase risk for complication, especially chronic laminitis2.

“Our new endocrinology tests, because of their rapidity and ease of use, will bring clinical
value for veterinary practices, directly at the Point of Care. Equine Metabolic Syndrome
and Cushing’s Disease are chronic conditions that often evade detection in their initial
stages, making early testing crucial in achieving proper management and animal care,”
explains Pierre Rouppert, Global Veterinary Product Manager at bioMérieux.

Laboratory standard hormone tests will become available in the UK at the Point of Care
using bioMérieux’s VIDAS® KUBE™ immunoanalyser, marking the first equine-focused
testing platform to launch with this capability. After the launch last June of VETFIRETM,
a cutting-edge PCR test for detecting respiratory infections in horses, bioMérieux
continues to transfer its expertise in the human testing sector to veterinary practice,
reducing wait times for results and enabling faster clinical decisions with the combined
diagnostic power of the two VIDAS® Equine endocrinology tests.

David Smart, Global Veterinary Business Developer at bioMérieux, says: “This dedicated
equine immunoassay test for insulin and ACTH represents a transformative step forward
in animal care. Veterinary practitioners will be able to achieve fast, reliable and cost-
effective laboratory grade results that can aid early detection and subsequent diagnosis
for two prolific and debilitating medical conditions in horses. The fast and accurate results
from these two new tests will allow quicker clinical decisions that will ultimately help more
horses receive an improved standard of care and reassure horse owners.”

With this scientifically precise, on-demand technological innovation, bioMérieux brings
to veterinary medicine its 60+ years of expertise in clinical diagnostics and continues to
expand its high-quality offering to meet the needs of the fast-moving veterinary and
equine sectors. The two new tests will initially be available in the United Kingdom and
France, with international rollout planned in the coming months.


1 Insulin dysregulation in a population of Finnhorses and associated phenotypic markers of obesity - PMC
2
Nicola Menzies-Gow, an update on latest research into equids, VetTimes, 21 Nov 2023
-Ends-

ABOUT BIOMÉRIEUX
Pioneering Diagnostics
A world leader in the field of in vitro diagnostics since 1963, bioMérieux is present in 45 countries and serves
more than 160 countries with the support of a large network of distributors. In 2024, revenues reached
€4 billion, with over 93% of sales outside of France.
bioMérieux provides diagnostic solutions (systems, reagents, software and services) which determine the
source of disease and contamination to improve patient health and ensure consumer safety. Its products
are mainly used for diagnosing infectious diseases. They are also used for detecting microorganisms in
agri-food, pharmaceutical and cosmetic products. www.biomerieux.com.

bioMérieux is listed on the Euronext Paris stock market.
Symbol: BIM – ISIN Code: FR0013280286
Reuters: BIOX.PA/Bloomberg: BIM.FP


CONTACTS

INVESTORS RELATIONS
bioMérieux
Aymeric Fichet
Tel: +33 (0)4 78 87 20 00
investor.relations@biomerieux.com

MEDIA RELATIONS
bioMérieux Ireland & United Kingdom
Romain Duchez Sarah Cawley (Hanover)
Tel: +33 (0)4 78 87 20 00 Tel: +44 (0)7817 688031
media@biomerieux.com scawley@hanovercomms.com